AOD-9604
HGH Fragment 177-191
Best For
Targeted fat reduction without hormonal disruption, adjunct to metabolic protocols
15aa
Amino acid fragment of the 191aa HGH molecule
0
Measurable effect on blood glucose or IGF-1
2x
Lipolytic activity vs. placebo in preclinical models
How It Works
AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone — the C-terminal fragment responsible for lipolytic activity. It stimulates lipolysis by mimicking the fat-mobilizing action of HGH without activating the IGF-1 axis or affecting blood glucose levels. This selective mechanism means it promotes triglyceride breakdown in adipose tissue and inhibits lipogenesis without the diabetogenic, acromegalic, or proliferative side effects associated with full-length growth hormone.
Key Research Areas
Targeted Fat Loss
Stimulates lipolysis in adipose tissue without systemic GH side effects
No IGF-1 Elevation
Does not raise insulin-like growth factor — avoids proliferative risks
Lipogenesis Inhibition
Blocks new fat cell formation while promoting existing fat breakdown
Metabolic Safety
No impact on blood glucose, insulin, or HbA1c in clinical observations
Research Highlights
- Isolates the fat-loss mechanism of growth hormone without systemic side effects
- Granted GRAS status by the FDA in 2007 for oral anti-obesity applications
Formulation Notes
Common concentrations referenced in published clinical studies:
[5AD]5mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Semaglutide
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgTirzepatide
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mg5-Amino-1MQ
NNMT Inhibitor for Fat Metabolism
- Entirely distinct from GLP-1 and amylin pathways — a new axis for metabolic support
- Targets fat storage at the enzymatic level rather than appetite signaling
Reference Codes
[5AM]5mg[50AM]50mgEvidence reviewed: March 2026